TABLE 1.

Outcomes of published studies using EGFR inhibitors for the treatment of recurrent glioblastoma

Authors & Year	Study Type & Trial Phase	No. of Patients	Prior Radio- & Chemotherapy Treatment	Current Intervention & Regimen	Radiographic Response	PFS	OS*
gefitinib	BBB permeability: limited
Rich et al., 2004	Phase II, open label,  single arm	53	radiotherapy, chemotherapy,  w/ repeat surgery/biopsy  documenting progression	gefitinib	CR (0%), PR (0%), SD (42%)	13% at 6mos	9.1 mos
Reardon et al., 2006	Phase I, clinical trial, dose  escalation	34	radiotherapy, chemotherapy	gefitinib & sirolimus	CR (0%), PR (5%), SD (38%)	23% at 6mos	not reported
Doherty et al., 2006	retrospective	28	radiotherapy, chemotherapy	gefitinb or erlotinib plus  sirolimus	CR(0%), PR (19%), SD(50%)	25% at 6mos	not reported
erlotinib	BBB permeability: good
de Groot et al., 2008	Phase II, clinical trial,  single arm	44	radiotherapy, chemotherapy	carboplatin & erlotinib	CR (0%), PR (2%), SD (47%)	median 2.1 mos,  14% at 6 mos	6.9 mos
van den Bent et al.,   2009	Phase II, clinical trial,  randomized, controlled	110	radiotherapy, chemotherapy	erlotinib vs temozolomide or  carmustine (if received  prior temozolomide)	CR (0%); erlotinib arm: PR (3.7%),  SD(16.7%); control: PR (9.6%),  SD (34.6%)	erlotinib: 11.4% at 6  mos; control:  24.1% at 6 mos	erlotinib: 7.7  mos; control:  7.3 mos
Raizer et al., 2010	Phase II, clinical trial,  single arm	38	radiotherapy, chemotherapy	erlotinib	CR (0%), PR (0%), SD (8%)	median 2 mos, 3%  at 6 mos	6 mos
Yung et al., 2010	Phase II, clinical trial,  single arm	48	radiotherapy, chemotherapy	erlotinib	CR(2%), PR (4%), SD(16°/c)	20% at 6 mos	8.6 mos
cetuximab	BBB: poor
Neyns et al, 2009	Phase II, clinical trial, 2  arms, noncomparative	55	radiotherapy, chemotherapy	cetuximab	CR(0%), PR (5%), SD (31%),	median 1.9 mos,  7.3% at 6 mos	5.0 mos, 37.9%  at 6 mos

^*Values are reported as the median or mean depending on the study.